Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital.

Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital.

<h4>Background</h4>Oritavancin is a lipoglycopeptide antibiotic with in vitro bactericidal activity against gram-positive pathogens indicated for use in adults with acute bacterial skin and skin structure infections (ABSSSI). Its concentration-dependent activity and prolonged half-life p...

Full description

Bibliographic Details
Main Authors: Kimberly Saddler, Jason Zhang, Jennifer Sul, Pruthvi Patel, Miriams Castro-Lainez, Mark L Stevens, Sheryl Kosler, Emily Lowery, Miguel Sierra-Hoffman
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0248129

Internet

https://doi.org/10.1371/journal.pone.0248129

Similar Items